Table 2 Virologic and Immunologic Outcomes for patients initiating HAART using an Intention to Treat Analysis.
Outcome | 1 year | 5 years | 8 years | ||||||
|---|---|---|---|---|---|---|---|---|---|
HAART Era | Total | Early | Late | Total | Early | Late | Total | Early | Late |
Median (IQR) # of viral loads available per patient | 4 (3-6) | 4 (3-6) | 5 (3-6) | 17 (12-23) | 18 (12-24) | 15 (12-19) | 26 (18-35) | 26 (18-35) | 20 (15-27) |
Virologic Suppression (n) | 1759 | 1216 | 543 | 1063 | 868 | 195 | 735 | 707 | 28 |
   Suppresseda | 1135 (64.5) | 693 (57.0)g | 442 (81.4) | 674 (63.4) | 508 (58.5)g | 166 (85.1) | 487 (66.3) | 464 (65.6) | 23 (82.1) |
   Always Suppressedb | 864 (49.1) | 478 (39.3)g | 386 (71.1) | 244 (23.0) | 172 (19.8)g | 72 (36.9) | 112 (15.2) | 104 (14.7) | 8 (28.6) |
   Ever Suppressedc | 1391 (79.1) | 890 (73.2) | 501 (92.3) | 991 (93.2) | 800 (92.2) | 191 (97.9) | 707 (96.2) | 680 (96.2) | 27 (96.4) |
Virologic Failured | 629 (35.8) | 525 (43.2)g | 104 (19.2) | 594 (55.9) | 527 (60.7)g | 67 (34.4) | 496 (67.5) | 482 (68.2)g | 14 (50. 0) |
   Never Suppressede | 368 (20.9) | 326 (26.8)g | 42 (7.7) | 72 (6.8) | 68 (7.8)g | 4 (2.1) | 28 (3.8) | 27 (3.8) | 1 (3.6) |
   Reboundf | 261 (14.8) | 199 (16.4)g | 62 (11.4) | 522 (49.1) | 459 (52.9)g | 63 (32.3) | 468 (63.7) | 455 (64.4) | 13 (46.4) |
Mean CD4, cells/mL | 488 ± 267 | 469 ± 268 | 530 ± 262 | 571 ± 306 | 562 ± 305 | 611 ± 307 | 556 ± 306 | 552 ± 301 | 657 ± 398 |
CD4 Change | 143 ± 180 | 126 ± 171g | 179 ± 193 | 220 ± 271 | 214 ± 270 | 247 ± 278 | 209 ± 288 | 206 ± 284 | 263 ± 362 |
CD4 Increase ≥ 30% | 880 (60.0) | 564 (56.9) | 316 (66.5) | 583 (66.9) | 461 (65.3) | 122 (73.5) | 381 (62.5) | 365 (62.6) | 16 (59.3) |
CD4 Increase ≥ 50% | 665 (45.4) | 418 (42.2) | 247 (52.0) | 489 (56.1) | 385 (54.5) | 104 (62.7) | 331 (54.3) | 318 (54.5) | 13 (48.1) |